Clinical Trial Update: Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial is evaluating Tafasitamab (MOR00208) in pediatric patients with relapsed or refractory acute lymphoblastic leukemia, currently recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• tafasitamab (tafasitamab)

Snippet

Sponsor: University Hospital Tuebingen | Conditions: ALL, Childhood B-Cell, Acute Lymphoid Leukemia Relapse | Phase 1, Phase 2 | Status: RECRUITING